

## PUBLIC HEALTH

## QUALITY OF LIFE IN PATIENTS WITH VITILIGO IN NORTH MACEDONIA

Natasia Teovska Mitrevska<sup>1</sup><sup>1</sup> "Remedika" General Hospital, Dermatology Department, Skopje, North Macedonia

## Abstract

**Citation:** Mitrevska Teovska N. Quality of life in patients with vitiligo in North Macedonia. Arch Pub Health 2023; 15 (2).

doi.org/10.3889/aph.2022.6108

Online First

**Key words:** vitiligo, quality of life index, psoriasis, alopecia areata, body surface area measurement index (BSA).**\*Correspondence:** Natasia Teovska Mitrevska, "Remedika" General Hospital, Dermatology Department, Skopje, North Macedonia.

E-mail: nteovska@remedika.com.mk

**Received:** 4-Sep-2023; **Revised:** 11-Nov-2023;**Accepted:** 12-Nov-2023; **Published:** 20-Nov-2023**Copyright:** © Natasia Teovska Mitrevska. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.**Competing Interests:** The author have declared that no competing interests

Vitiligo is an acquired depigmentation deficit with a high prevalence, ranging from 0.5% to 7.8%. The aim of the study was to measure the quality of life (QL) of patients with vitiligo, expressed through the Dermatological Quality of Life Index (DLQI). Materials and methods: This cross-sectional study was realized in a period of 1 year. Two questionnaires were used in the study. The first questionnaire contains data from the DLQI, designed for use in adults over 16 years of age, taken from the Cardiff University in the UK. The second questionnaire contains demographic and clinical characteristics of patients (age, gender, place of residence, marital status, education), activity, comorbid diseases and BMI, age at onset, site of onset of lesions, duration of disease, family history, type, activity, natural course, body mass index (BMI) and therapy. Results: Among 71 subjects included in the study, the total score of the DLQI ranged from 0 to 28 (from a maximum of 30 points), and the average was  $11.70 \pm 5.7$ . Female patients had greater QL impairment (total mean value of 8.03) than men (5.99); there was a statistically significant difference between both sexes ( $P = 0.019$ ). The total score of QL in terms of symptoms related to the condition in the six domains strongly affected QL of 45.1% of patients. The QL was significantly worse in the studied group of 16-30 years ( $13.85 \pm 5.3$ ) compared to the population of 51-60 and over 60 years ( $6.75 \pm 5.7$ , and  $7.0 \pm 2.3$ ). As the age of patients advanced, the QL improved. Subjects with higher education had a higher score ( $14.41 \pm 6.6$ ;  $p=0.001$ ). Conclusion: Female patients with vitiligo have impaired QL in comparison to male. With age, the QL in patients with vitiligo improves. Patients with a lower degree of education have a better QL.

## ЈАВНО ЗДРАВЈЕ

## КВАЛИТЕТ НА ЖИВОТ НА ПАЦИЕНТИ СО ВИТИЛИГО ВО СЕВЕРНА МАКЕДОНИЈА

Наташа Теовска Митревска<sup>1</sup><sup>1</sup> Општа болница „Ремедика“, Оддел за дерматологија, Скопје, Северна Македонија

## Извадок

**Цитирање:** Митревска Теовска Н. Квалитет на живот на пациенти со витилиго во Северна Македонија Арх Ј Здравје 2023;15(2)

doi.org/10.3889/aph.2022.6108

Online First

**Клучни зборови:** витилиго, индекс на квалитет на живот, псориаза, алопеција ареата, индекс за мерење на површината на телото.**\*Кореспонденција:** Наташа Теовска Митревска, Општа болница „Ремедика“, Оддел за дерматологија, Скопје, Северна Македонија.

E-mail: nteovska@remedika.com.mk

**Примено:** 4-сеп-2023; **Ревидирано:** 1-ное-2023;**Прифатено:** 12-ное-2023; **Објавено:** 20-ное-2023**Печатарски права:** ©2023. Наташа Теовска Митревска. Оваа статија е со отворен пристап дистрибуирана под условите на нелокализирана лиценца, која овозможува неограничена употреба, дистрибуција и репродукција на било кој медиум, доколку се цитираат оригиналниот(ите) автор(и) и изворот.**Конкурентски интереси:** Авторот изјавува дека нема конкурентски интереси.

Витилиго е стекнат дефицит на депигментација со висока преваленција, која се движи од 0,5% до 7,8%. Целта на студијата беше да се измери квалитетот на живот (КЖ) кај пациенти со витилиго, изразен преку Дерматолошкиот индекс на квалитет на животот (ДИКЖ). Материјали и методи: Оваа студија на пресек беше реализирана во временски интервал од 1 година. Во студијата беа користени два прашалника. Првиот прашалник содржи податоци од ДИКЖ, дизајниран за употреба кај возрасни лица, постари од 16 години, преземен од Универзитетот Кардиф во Велика Британија. Вториот прашалник содржи демографски и клинички карактеристики (возраст, пол, место на живеење, брачен статус, образование), активност, коморбидни заболувања и БМИ, возраст на почетокот, место на појава на лезии, времетраење на болеста, семејна историја, тип, активност, природен тек, БМИ и терапија. Резултати: Кај 71 испитаник вклучени во студијата, вкупниот скор за ДИКЖ се движеше во опсег од 0 до 28 (од максимални 30 поени), а просечно изнесуваше  $11.7 \pm 5.7$ . Женските пациенти имаа поголемо оштетување на КЖ (вкупна средна вредност од 8,03) од мажите (5,99); постои статистички значајна разлика помеѓу резултатите за двата пола ( $P = 0,019$ ). Вкупниот скор за квалитетот на животот од аспект на симптомите поврзани со состојбата на кожата кај пациентите со витилиго, во шесте домени, силно го афектираа квалитет на животот на 45,1% од нив. Квалитетот на животот беше значајно полош кај испитуваната група од 16 до 30 години ( $13,85 \pm 5,3$ ) во споредба со популацијата од 51 до 60 и над 60 години ( $6,75 \pm 5,7$ , и  $7,0 \pm 2,3$ ) во поглед на дневните активности и слободни активности и тераписки третман. Со напредување на возраста на пациентите со витилиго, се подобрува квалитетот на животот. Испитаниците со повисоко образование имаа повисок ДИКЖ скор ( $14,41 \pm 6,6$ ;  $p = 0,001$ ). Заклучок: Женските пациенти имаат полош КЖ во споредба со машките. Со возраста, КЖ кај пациенти со витилиго се подобрува. Пациентите со понизок степен на образование имаат подобар КЖ.

## Introduction

Quality of life (QL) is defined by the WHO (World Health Organization) as the perception of individuals about their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.<sup>1</sup> This definition reflects the view that quality of life is a multidimensional index that refers to a subjective evaluation that is embedded in a cultural, social and environmental context.<sup>1</sup>

Vitiligo is an acquired de-pigmentary disease characterized by white macules on the skin, mucous membranes and hair due to the selective destruction of melanocytes.<sup>2</sup>

According to the definition of Vitiligo European Working Group, vitiligo vulgaris is an acquired chronic pigmentation disorder characterized by white macules, often symmetrically distributed, which usually increase in size over time, corresponding to a significant loss of function of epidermal and sometimes hair follicle-melanocytes.<sup>3</sup> Following the classic morphology of vitiligo, the lesions are discrete, uniformly milky-white macules of round, oval, or irregular shape ranging in size from millimeters to many centimeters, surrounded by normal or hyperpigmented skin. The disease is asymptomatic, but in some cases itching or a burning sensation may occur. Although vitiligo does not cause direct physical impairment, it is commonly believed that it can produce an important psychosocial burden. Several authors report that patients with

vitiligo suffer from poor body image, low self-esteem and that they experience a high level of disability from their skin disease.<sup>3-6</sup> Vitiligo patients feel distressed and stigmatized by their condition, especially in relation to social activities. It is also believed that exposing the body causes anxiety and embarrassment, and may have a negative effect on sexual relationships.

The aim of the study was to measure the quality of life (QL) of patients with vitiligo, expressed through the Dermatological Quality of Life Index (DLQI).

## Materials and methods

This research was the first in North Macedonia that measured the quality of life in patients with vitiligo. This cross-sectional study was conducted in a period of one year (2021). Two questionnaires were used: the Dermatology Quality of Life Questionnaire from the Cardiff University, UK with consent obtained from Prof. Finlay *et al.*, translated in Macedonian language, and the second questionnaire which contained questions about demographic characteristics and disease activity.<sup>3</sup> All subjects/patients who met the selection criteria were included in the study. DLQI questionnaire includes 10 items about a patient's feelings and many aspects of the illness that occurred in the last 7 days. Questions include "vitiligo symptoms" (itching, pain, irritation), "feelings" (shame, anxiety and anger), "everyday activities" (shopping and activities in the home), "type of clothing", "social or leisure activities", "physical exercis-

es”, “educational activities”, “sexual activities”, “interpersonal relations” (with husband/s, friends, relatives) and ‘treatment opportunities’. Each item is scored on a scale from four points (3 = a lot, 2 = moderately, 1 = a little, 0 = not at all). The total score of DLQI was calculated by summing the score of each of the 10 questions assessed and interpreted: as no impairment of quality of life (0–1), minor damage (2–5), moderate damage (6–10), severe damage (11–20), or a serious severe impairment (21–30). In the second questionnaire, the data was filled out by the researcher of the Department of dermatology in “Remedika” Private General Hospital after a clinical examination of the patient and includes data on age, sex, place of residence, education, marital status, Fitzpatrick skin type, comorbid diseases (hyperlipidemia, diabetes mellitus type 1, hyperthyroidism, hypothyroidism, pernicious anemia, alopecia areata, ophthalmic abnormalities), familial history of the disease, use of alcohol, cigarettes, BMI. Data related to vitiligo include age at onset, family history of vitiligo, therapeutic history (with or without therapy), type of vitiligo (non-segmental, segmental and unclassified), vitiligo activity (in years), the natural flow (stable, unstable and with regression) and percentage of occupation of body surface. The localization and type of the disease were diagnosed with standard physical examination and using Wood’s light. The percentage of skin area involved was calculated using the rule of nine undertaken from the Vitiligo European Task Force (VETF).<sup>4</sup>

## Statistical analysis

Data analysis was performed using the statistical programs Statistics 7.1 for Windows and SPSS Statistics 23.0. The quality of life in patients with vitiligo were analyzed with Dermatological Quality of Life Index, where by the internal consistency between the answers to the 10 questions was assessed by making Reliability Statistics - Cronbach’s Alpha / Total score / Average score.

## Results

A total of 71 patients with vitiligo were included in the study, of which 38 (53.5%) were male and 33 (46.5%) female patients. Demographic data and patient characteristics are presented in Table 1. Patients were aged 16 to 30 and 31 to 40 years, 27 (38%) and 23 (32.4%) patients, consequently. According to place of residence, majority of patients - 48 (67.6%) were from urban areas. Unmarried were 35 (49.3%) patients, the same number of patients were married, and one patient was a widow. Body mass index usually ranged from 25 to 29.9 kg/m<sup>2</sup>, that is, most of the subjects were overweight. Ten (12.7%) patients were obese, with values of the index higher than 30 kg/m<sup>2</sup>. Forty patients (56.3%) declared themselves as active cigarette smokers. Among them, 6 patients (8.45 %) smoked more than 20 cigarettes per day. Subjects mostly consumed less than one glass of alcohol per week - 45 patients (63.4%).

**Table 1.** Characteristics of recruited patients

Patients' characteristics	n (%)
<b>Gender</b>	
Male	38 (53.5 %)
Female	33 (46.4 %)
<b>Age/years</b>	
16 - 30	27 (38 %)
31 - 40	23 (32.3 %)
41 - 50	11 (15.4 %)
51 - 60	4 (5.6 %)
> 60	6 (8.4 %)
<b>Place of residence</b>	
Village	23 (32.3 %)
Urban/city	48 (67.6 %)
<b>Marital status</b>	
Unmarried	35 (49.2 %)
Married	35 (49.2 %)
Widow	1 (1.4 %)
<b>BMI kg/m<sup>2</sup></b>	
18.6 - 24.9	28 (39.4 %)
25 -29.9	34 (47.8 %)
30 - 34.9	4 (5.6 %)
35 - 39.9	3 (4.2 %)
> 40	2 (2.8 %)
<b>Smoking (cigarettes /daily)</b>	
Never	31 (43.6 %)
1 - 5	13 (18.3 %)
6 - 10	12 (16.9 %)
11 - 20	9 (12.6 %)
> 20	6 (8.4 %)
<b>Consuming alcohol</b>	
consume less than one glass of alcohol per week	45 (63.38 %)
1 - 3 glass of alcohol	24 (33.80 %)
4 glass of alcohol	2 (2.82 %)

More than half of the subjects, 42 patients (59.1%), had a positive family history of vitiligo. Anamnestic data presented that the appearance of vitiligo was at the ages of 16 and 30, 21 patients (29.6%). In 19 patients (26.8%) the disease first appeared at the age between 11 and 15 years. By the age of five, the disease was diagnosed in 11 patients (15.5%). Itching as a symptom of the disease appeared in 27 (38%) patients. Positive Koebner phenomenon, i.e., appearance of vitiligo in places of previous skin trauma was registered in 42

patients (59.15 %). In this study, patients had the most common 4 types of vitiligo: non-segmental, rofacial, mixed type, non-segmental focal, and segmental focal type, found in 15 patients (21.1%), 14 (19.7%), 13 (18.3%), and 10 (14.1%) patients, respectively. In more than half of the subjects, that is, in 41 (57.75%) patients the disease was stable, and did not spread over the last year.

The total score of DLQI ranged from 0 to 28 (out of a maximum of 30 points), and the average was  $11.70 \pm 5.7$  (Table 2).

**Table 2.** Mean DLQI scores of the sample according to different heading items and rates of answers

	mean $\pm$ SD	min-max	95 % CI
Symptoms and feelings	2.75 $\pm$ 1.4	0 - 6	1.2 - 1.7
Daily activities	2.51 $\pm$ 1.4	0 - 6	1.2 - 1.7
Leisure	2.13 $\pm$ 1.5	0 - 6	1.3 - 1.8
Work and school	1.14 $\pm$ 1.3	0 - 4	1.1 - 1.5
Personal relationship	2.04 $\pm$ 1.7	0 - 6	1.5 - 2.1
Treatment	1.15 $\pm$ 0.98	0 - 3	0.8 - 1.2
Total	11.70 $\pm$ 5.7	0 - 28	4.9 - 6.9

**Table 3.** DLQI score according to Hongbo *et al.*<sup>5</sup>

	n (%)
0-1 no effects on patients' lives	3 (4.22%)
2-5 small effects	6 (8.45%)
6-10 moderate	24 (33.8 %)
11-20 very large	32 (45.07 %)
21-30 extremely large	6 (8.45 %)

## Discussion

Skin diseases affect different aspects of patients' lives and how successful treatment may improve patients' quality of life (QL). The number of publications on QL in dermatology has been constantly growing each year over the last 20 years.

The total DLQI in all subjects with vitiligo in our study was  $11.70 \pm 5.72$ . Among male subjects, the score was  $10.34 \pm 5.7$ , and  $13.27 \pm 5.4$  in the group of female patients with vitiligo. The difference between both groups was 2.93, which was statistically significant. The significance was evident in performing daily activities. In the present study, the DLQI mean score was statistically higher in female patients than in male. The greater impairment of QL in females affected by vitiligo is under debate.

If we compare the research data published from 1996 to 2012, the mean scores of the DLQI for vitiligo across the world ranged from 1.82 to 15, and the overall mean was 8.2, indicating a moderate effect of the QL. In fact, some studies showed a higher DLQI mean score in female patients.<sup>7-25</sup>

Ongenaes *et al.* noted that women were more embarrassed and self-conscious about the disease, more impaired in their daily routine and more influenced in their choice of clothing than men.<sup>9,10,30,31</sup> In our study, the age of the studied group of patients with vitiligo had a significant statistical impact on the quality of life. The quality of life was significantly worse in the study group of 16–30 years compared to the population of 51–60 and over 60 years in terms of symptoms, daily activities and leisure activities and treatment.

With advancing age, the quality of life of vitiligo patients improved.

In the present study, the DLQI mean score was statistically higher in female patients than in male. The greater impairment of QL in females affected by vitiligo is under debate. In fact, some studies showed a higher DLQI mean score in female patients in a selected sample. In contrast, several authors pointed out the same impairment of QL between sexes. The mean scores of the DLQI across the world ranged from 1.82 to 15, and the overall mean was 8.2, indicating a moderate effect of the QL.

Identical results to ours were presented in the study by Budania *et al.*, with an average score of 11.52, as well as in the study by Sahni *et al.*, with an average score of 11.42, and Parsad with an average score of 10.70.<sup>26-29</sup>

Compared to other dermatological diseases, the QL in patients with vitiligo in our study was the same as in patients with psoriasis. In the literature, patients with psoriasis had more impaired disease-related quality of life than vitiligo and alopecia areata patients.<sup>31-33</sup> In a study performed by Ongenaes *et al.*, patients with vitiligo were compared to psoriasis patients. They found a mean DLQI score of vitiligo that was lower than the score obtained for psoriasis.

The QL in patients with vitiligo was significantly worse compared to melasma and significantly better compared to psoriasis.<sup>33</sup>

## Conclusion

This research was the first in North Macedonia that measured the quality of life in patients with vitiligo. The

goal was to detect patients who were at risk of poor quality of life and to identify the variables that could predict this QL impairment. Also, this study aimed to provide an additional and significant boost in the development and improvement of quality standards in the support of vitiligo patients.

Patients in our study showed a moderate limitation of QL, comparable to that of other chronic skin diseases. Limitations of this study include a small study sample, as well as possible selection bias as participating patients were recruited from the Dermatology center in the “Remedika” General Hospital, Skopje N. Macedonia.

Further multi-centric studies are needed to validate the results. Females were shown to be more affected by vitiligo in all dimensions of the scale.

It should be emphasized that efforts of the management should focus on psychosocial and economic factors, especially in females, in addition to therapeutic efforts and hence better QL and treatment outcomes.

## References

1. The WHOQOL Group. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. *Soc Sci Med.* 1998; 46(12):1569-85. DOI:10.1016/s0277-9536(98)00009-4
2. Rosenberg M. *Conceiving the Self.* New York: Basic Books.1979. doi.org/10.2307/3340091
3. Taïeb A. The definition and assessment of vitiligo: A consensus report of the Vitiligo European Task Force, Pigment Cell Research. 2007;20(1):27 – 35. DOI:10.1111/j.1600-0749.2006.00355.x
4. Taïeb A. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. *Pigment Cell Melanoma Res.* 2012; 25(3): E1-13. DOI: 10.1111/j.1755-148X.2012.00997.x
5. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? *J Invest Dermatol* 2005;125:659–664. DOI:10.1111/j.0022-202X.2005.23621.x
6. Kent G, Al-Abadie M. Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. *Clin Exp Dermatol.*1996;21:330–333. doi.org/10.1111/j.1365-2230.1996.tb00116.x
7. Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. *Health Qual Life Outcomes* 2003;1:58. DOI:10.1186/1477-7525-1-58
8. Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY: DLQI scores in vitiligo: reliability and validity of the Persian version. *BMC Dermatol*2004;4:8. doi:10.1186/1471-5945-4-8
9. Ongenaë K, van Geel N, De Schepper S, Nae-yaert JM. Effect of vitiligo on self-reported health-related quality of life. *Br J Dermatol* 2005;152:1165–1172. DOI:10.1111/j.13652133.2005.06456.x
10. Ongenaë K, Dierckxsens L, Bro-

- chez L, vanGeel N, Naeyaert JM. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. *Dermatology* 2005;210:279–285. DOI:10.1159/000084751
11. Mechri A, Amri M, Douarika AA, Ali Hichem BH, Zouari B, Zili J. Psychiatric morbidity and quality of life in vitiligo: a case controlled study. *Tunis Med* 2006;84:632–635. DOI: 10.17354/ijss/2015/461
  12. Van Geel N, Ongenaes K, Vander Heghen Y, Vervaeck C, Naeyaert JM. Subjective and objective evaluation of non-cultured epidermal cell-lular grafting for repigmenting vitiligo. *Dermatology* 2006; 213:23–29. DOI:10.1159/000092833
  13. Belhadjali H, Amri M, Mecheri A, Doarika A, Khorchani H, Youssef M *et al.* Vitiligo and quality of life: a case-control study. *Ann Dermatol Venereol* 2007;134:233–236. DOI:10.1016/s0151-9638(07)91814-1
  14. Al Robaee AA. Assessment of quality of life in Saudi patients with vitiligo in a medical school in Qassim province, Saudi Arabia. *Saudi Med J* 2007;28:1414–1417. doi: 10.15537/smj.2021.42.6.20200833
  15. Dolatshahi M, Ghazi P, Feizy V, Hemami MR. Life quality assessment among patients with vitiligo: comparison of married and single patients in Iran. *Indian J Dermatol Venereol Leprol* 2008;74:700. DOI:10.4103/0378-6323.45141
  16. Kostopoulou P, Jouary T, Quintard B, Ezze-dine K, Marques S, Boutchnei S, Taieb A. Objective vs subjective factors in the psychological impact of vitiligo: the experience from a French referral centre. *Br J Dermatol* 2009;161:128–133. DOI:10.1111/j.1365-2133.2009.09077.x
  17. Radtke MA, Schäfer I, Gajur A, Langenbruch A, Augustin M: Willingness-to-pay and quality of life in patients with vitiligo. *Br J Dermatol* 2009;161:134–139. DOI:10.1111/j.1365-2133.2009.09091.x
  18. Mashayekhi V, Javidi Z, Kiafar B, Manteghi AA, Saadatian V, Esmaeili HA, Hosseinaliza-deh S. Quality of life in patients with vitiligo: a descriptive study on 83 patients attending a PUVA therapy unit in Imam Reza Hospital, Mashad. *Indian J Dermatol Venereol Leprol* 2010;76:592. DOI:10.4103/0378-6323.69097
  19. Wang KY, Wang KH, Zhang ZP. Health-related quality of life and marital quality of vitiligo patients in China. *J Eur Acad Dermatol Venereol* 2011;25:429–435. DOI:10.1111/j.1468-3083.2010.03808.x
  20. Chan MF, Chua TL, Goh BK, Aw CW, Thng TG, Lee SM. Investigating factors associated with depression of vitiligo patients in Singapore. *J Clin Nurs* 2011;21:1614–1621 DOI:10.1111/j.1365-2702.2011.03777.x
  21. Wong S, Bao MBBCH, Baba R. Quality of life among Malaysian patients with vitiligo. *Int J Dermatol* 2012;51:156–161. doi. org/10.1159/000448656



22. Ingordo V, Cazzaniga S, Gentile C, Iannazzone SS, Cusano F, Naldi L. Dermatology Life Quality Index score in vitiligo patients: a pilot study among young Italian males. *G Ital Dermatol Venereol* 2012;147:83–90. doi: [10.1159/000363407](https://doi.org/10.1159/000363407)
23. Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life. *JAMA Dermatol* 2013; 149:159–164. DOI:10.1001/jama-dermatol.2013.927
24. Kiprono S, Chaula B, Makwaya C, Naafs B, Masenga J. Quality of life of patients with vitiligo attending the Regional Dermatology Training Center in Northern Tanzania. *Int J Dermatol* 2013;52:191–194. DOI:10.1111/j.1365-4632.2012.05600.
25. Karelson M, Silm H, Kingo K: Quality of life and emotional state in vitiligo in an Estonian sample: comparison with psoriasis and healthy controls. *Acta Derm Venereol* 2013;93:446–450. DOI:10.2340/00015555-1520
26. Parsad D. Clinical and molecular aspects of vitiligo treatments. *Int J Mol Sci* 2018;19(5):1509. DOI: 10.3390/ijms19051509
27. Budania A, Parsad D, Kanwar AJ, Dogra S. Comparison between autologous noncultured epidermal cell suspension and suction blister epidermal grafting in stable vitiligo: a randomized study. *Br J Dermatol* 2012;167:1295–1301. DOI: 10.1111/bjd.12007
28. Eleftheriadou V, Hamzavi I, Pandya AG, Grimes P, Harris JE, Huggins RH, *et al.* International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation. *Br J Dermatol* 2019;180(3):574–9. DOI:10.1111/bjd.17013
29. Christina B, Khaled E. Vitiligo: A focus on pathogenesis and its therapeutic implications. *J Dermatol* 202;48(3):252-270. doi: 10.1111/1346-8138.15743
30. Batchelor JM, Gran S, Leighton P, Howells L, Montgomery AA. Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpretability, reliability and acceptability. *Br J Dermatol* 2022;187(4):548-556. doi: 10.1111/bjd.21671.
31. Pandya AG, Ezzedine K. Noticeability of vitiligo is in the eye of the beholder. *Br J Dermatol* 2022;187(4):461-462. doi: 10.1111/bjd.21779.
32. Porter JR, Beuf AH, Lerner A, Nordlund J. Psychosocial effect of vitiligo: a comparison of vitiligo patients with “normal” control subjects, with psoriasis patients, and with patients with other pigmentary disorders. *J Am Acad Dermatol* 1986;15(2 Pt 1):220-4. doi:10.1016/s0190-9622(86)70160-6
33. Ghajarzadeh M, Ghiasi M, Kheirkhah S. Associations between skin diseases and quality of life: a comparison of psoriasis, vitiligo, and alopecia areata. *Acta Med Iran*. 2012;50(7):511-5. PMID: 22930385.